 Steroid-induced weakness patients primary brain tumors Clinically significant steroid myopathy SM adult patients primary brain tumors continuous weeks daily dexamethasone therapy SM wide range peak cumulative doses dexamethasone wide range periods continuous treatment random event two-thirds patients weakness week continuous dexamethasone treatment risk SM patients phenytoin patients anticonvulsants patient treatment factor SM possible direct correlation appearance cushingoid body habitus retrospective review occurrence SM significant negative impact quality life affected individuals patients reduction steroid dose patients combined effects tumor progression myopathy nonfluorinated glucocorticoid dexamethasone advisable neuro-oncology patients SM steroids